Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARACAS study
2018-000737-12Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anal squamous cell carcinoma (SCCA) comparing cetuximab + avelumab with avelumab alone (2 arms). Primary endpoint: Objective response rate. Started Nov 2020; status: completed.
02
Drugs
cetuximabavelumab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2018-000737-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000737-12.